Merck & Co.'s Strong Franchises in Vaccines and Animal Health

Merck & Co. (NYSE:MRK) has strong franchises in vaccines and animal health, as well as promising pipeline experiments combining KEYTRUDA with other drugs to target specific cancers. Analysts highlight these growth catalysts for the stock, despite concerns about generic competition and market sentiment around healthcare stocks.

Merck & Co. (NYSE:MRK) has expanded its portfolio with the acquisition of Verona Pharma plc, a biopharmaceutical company focused on respiratory diseases. The deal, announced on July 8, 2025, involves Merck acquiring Verona Pharma for $107 per American Depository Share (ADS), representing a total transaction value of approximately $10 billion Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade^[1].

The acquisition aligns with Merck's science-led business development strategy and adds Ohtuvayre® (ensifentrine), a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), to Merck's growing cardio-pulmonary pipeline and portfolio. Ohtuvayre, approved by the U.S. Food and Drug Administration in June 2024 for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients, is the first novel inhaled mechanism for the treatment of COPD in more than 20 years Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade^[1].

The acquisition complements Merck's existing franchises in vaccines and animal health and its promising pipeline experiments combining KEYTRUDA with other drugs to target specific cancers. Analysts highlight these growth catalysts for the stock, despite concerns about generic competition and market sentiment around healthcare stocks .

Verona Pharma's Ohtuvayre combines bronchodilator and non-steroidal anti-inflammatory effects, addressing an important unmet need for COPD patients persistently symptomatic. The drug is also being evaluated in clinical trials for the treatment of non-cystic fibrosis bronchiectasis. Merck's commercial footprint and industry-leading clinical capabilities are expected to accelerate the potential of Ohtuvayre to reach more patients living with COPD Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade^[1].

The acquisition is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act, approval of Verona Pharma shareholders, sanction by the High Court of Justice of England and Wales, and other customary conditions. The transaction is expected to close in the fourth quarter of 2025 and will result in the capitalization of most of the purchase price as an intangible asset for Ohtuvayre Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade^[1].